BostonGene and the SWOG Cancer Research Network are launching a Phase II trial leveraging multiomic platforms to identify molecular subtypes of extensive-stage small cell lung cancer, aiming to tailor targeted maintenance therapies. Meanwhile, Vanderbilt University Medical Center and Parse Biosciences collaborate on antibody repertoire sequencing to better understand immune diversity following MMR vaccination. These initiatives illustrate growing trends toward precision medicine and biomarker-driven therapeutic strategies in oncology.